Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | CDK4 | P11802 | 1/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1050281 | 0.89 | CCNB2 (0.59) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL28129638 | 0.88 | KDM4E (0.60) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL1125006 | 0.88 | KDM4E (0.60) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL7097452 | 0.88 | ERN1 (0.50) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL411835 | 0.87 | HTR1A (0.56) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL410058 | 0.84 | MAPT (0.69) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL9597698 | 0.84 | RAB9A (0.52) | ERN1TDP1L3MBTL1CA1CA2 | |
| SCHEMBL16632680 | 0.84 | KMT2A (0.54) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL17750764 | 0.84 | NFE2L2 (0.51) | CCNB2CDK1CDK4CCNB1CCND1 | |
| SCHEMBL17912878 | 0.84 | MAPT (0.66) | MAPTMAPK1TDP1L3MBTL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6210816-B1 | Translucent xerographic recording substrates | XEROX CORPORATION | 2001-04-03 | — | — | US | claimed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3286191-B1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2020-02-25 | — | — | US | disclosed |
| EP-3194367-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | Boehringer Ingelheim International GmbH (DE) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016169911-A1 | NOVEL DIHYDROPYRIDOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2016-10-27 | — | — | WO | disclosed |
| US-9340510-B2 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| WO-2016041845-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-03-17 | — | — | US | disclosed |
| US-7625887-B2 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20090239839-A1 | RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20070129348-A1 | Receptor antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20060199795-A1 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1623710-A1 | RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1591120-A1 | RECEPTOR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6210816-B1 | Translucent xerographic recording substrates | XEROX CORPORATION | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075657-A1 | Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof | QDPR, RECQL, TPMT | CCNB2 284/4885CDK1 393/4885CDK4 397/4885 |
| US-10568879-B2 | Dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GPR84, GPR88, GPR65 | CCNB2 3086/4885CDK1 1631/4885CDK4 1232/4885 |
| US-20090239839-A1 | RECEPTOR ANTAGONIST | FSHR, NR0B2, NR4A3 | CCNB2 3085/4885CDK1 2686/4885CDK4 3055/4885 |
| US-20070129348-A1 | Receptor antagonist | FSHR, NR0B2, NR4A3 | CCNB2 3085/4885CDK1 2686/4885CDK4 3055/4885 |
| US-20060199795-A1 | Receptor agonists | GPBAR1, GPR35, GPR55 | CCNB2 4380/4885CDK1 3306/4885CDK4 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.